Search
forLearn
5 / 801 resultslearn LHA™
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn heptyl glucoside
learn HYDROXYPROPYLAMMONIUM GLUCONATE
Research
5 / 433 results
research Simultaneous determination of multi-class active pharmaceutical ingredients by UHPLC-HRMS
A new method was developed to accurately detect and measure 47 different drug ingredients in various products.
research Characterization of spironolactone and metabolites derivatized using Girard's reagent P using mass spectrometry and ion mobility spectrometry
Girard's reagent P improves detection of spironolactone and its metabolites.
research Phytochemical profiling and evaluation of the anti-aging and anti-inflammatory potential of cultivated Eclipta alba (L.)
Eclipta alba has anti-aging and anti-inflammatory properties, making it a potential ingredient for cosmetics.
research Steroidomics for highlighting novel serum biomarkers of testosterone doping
Monitoring steroid hormones in blood can better detect testosterone doping.
research A quantitative ultra-performance liquid chromatography high-resolution mass spectrometry analysis of steroids from human scalp hair
The method can measure multiple steroids in human hair to study long-term steroid metabolism, especially in newborns and children.
Community Join
5 / 1000+ resultscommunity EveryChem 3HP / PP30 page data vs NMR PDFs in their website : metadata mistake or document mismatch?
There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.
community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.